iRadimed 10-Q Details Record Q3: $24.2M Revenue, $0.51 EPS, $0.20 Dividend
IRMD is trading near its 52-week low of $75.75 (0.9% above the low) on elevated volume (1.8× avg).
Summary
iRadimed's Q3 10-Q backs up the morning's record $24.2 million revenue and $0.51 EPS, showing gross margin down to 76% and cash up to $63.3 million, plus a $0.20 quarterly dividend and a CEO 10b5-1 plan for up to 50,000 shares.
Key Events · Earnings and Guidance · IRMD
-
Record Q3 Revenue of $24.2M
Revenue rose 14% to $24.2 million from $21.2 million a year earlier, with international sales up 45% to $4.5 million and U.S. sales up 9% to $19.7 million.
-
Gross Margin Slips to 76%
Gross profit of $18.5 million came at a 76% margin versus 78% a year ago, which management attributes to initial production inefficiencies on new product manufacturing.
-
Cash Builds to $63.3M
Cash and equivalents reached $63.3 million at September 30 from $51.2 million at December 31, 2025, after $21.2 million of nine-month operating cash flow and $7.7 million of dividends paid.
-
$0.20 Quarterly Dividend Declared
The board declared a regular quarterly cash dividend of $0.20 per share, payable November 27, 2026 to stockholders of record on November 13, 2026.
Analysis · IRMD · Industrial Applications And Services
With the headline numbers already out this morning via 8-K and newswires, the 10-Q's real value lies in the underlying quality of the quarter and the balance sheet. Revenue of $24.2 million rose 14%, but gross margin slipped to 76% from 78% on initial production inefficiencies for new products — growth is coming partly at the cost of margin. Cash built to $63.3 million from $51.2 million at year-end on $21.2 million of nine-month operating cash flow, and the board declared the regular $0.20 quarterly dividend payable November 27. Separately, CEO Roger Susi put a 10b5-1 plan in place on August 7 covering up to 50,000 shares through February 10, 2027 — a pre-scheduled selling window, not a discretionary sale.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRMD was trading at $76.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $980.5M. The 52-week trading range was $75.75 to $107.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.